乳腺癌组织ezrin、nm-23和VEGF的表达及临床意义

Expression and significance of ezirn,VEGF and nm-23 proteins in breast cancer

目的探讨乳腺癌组织中膜-细胞骨架联接蛋白埃兹蛋白(ezrin)、肿瘤转移抑制因子(nm-23)和血管内皮生长因子(VEGF)等蛋白表达与乳腺癌临床因素及预后的关系。方法应用免疫组化S-P方法检测63例手术切除的乳腺癌组织标本中ezirn、nm-23、VEGF的表达,并与临床进行对比分析。结果ezirn、nm-23和VEGF阳性表达率分别为55.56%、52.38%和65.08%)。三项指标与淋巴结转移、临床分期及无病生存时间均密切相关(P<0.05),但与年龄、肿块大小及月经情况均无相关性。结论Ezirn、nm-23和VEGF在乳腺癌组织中表达较高,可能对其发展起促进作用,并可能作为评价预后的指标。

Objective To explore the expression and clinical significance of ezrin,non-metastatic gene（nm-23）and vascular endothelial growth factor（VEGF）in breast cancer.Methods Immuno-histochemical staining was used to detect the expressions of ezrin,nm-23 and VEGF in 63 breast cancer samples.Results In 63 cases of breast cancer,the positive expression rates of ezrin,nm-23 and VEGF were 55.56% 52.38% and 65.08%,respectively,which were closely correlated with lymph node metastasis,stage of the disease and DFS time（P0.05）,but not with tumor size,age and menopausal status.Conclusion Abnormally higher expressions of ezrin,nm-23 and VEGF in the breast cancer patients may play the roles in the development of breast cancer,and could be the useful parameters to predict the prognosis of patients with breast cancer.